Fresh allegations hit Lancet hydroxychloroquine study
The journal has since published an 'expressions of concern' declaration on the study
The row over a Lancet paper warning against hydroxychloroquine treatment for COVID-19 has flared again with new claims it relied on data from a company led by a surgeon named in three medical malpractice lawsuits.
The observational study of 15,000 patients concluded the drug had no therapeutic benefit against COVID-19 and increased the risk of death by 35-45%.
